Thai Translation and Validation of Chronic Rhinosinusitis‐Patient Reported Outcome (CRS‐PRO)
Authors:
- Wirach ChitsuthipakornWCWirach Chitsuthipakorn
- Vorachai PooldumVPVorachai Pooldum
- Juthaporn PhetpongJPJuthaporn Phetpong
- Saranath LawpoolsriSaranath Lawpoolsri
- Dichapong KanjanawaseeDKDichapong Kanjanawasee
- Patlada KowatanamongkonPKPatlada Kowatanamongkon
- Kittichai MongkolkulKMKittichai Mongkolkul
- Kachorn SeresirikachornKSKachorn Seresirikachorn
- Kornkiat SnidvongsKSKornkiat Snidvongs
Open Access
- 17 March 2026
- journal article
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Abstract
Objectives: The Chronic Rhinosinusitis Patient‐Reported Outcome (CRS‐PRO) questionnaire was recently developed for use in chronic rhinosinusitis (CRS) patients. This instrument was developed using current diagnostic criteria. This study aimed to translate and validate CRS‐PRO for Thai CRS patients. Methods: The three‐phase translation process and validation were conducted at Rajavithi Hospital, a tertiary hospital in Bangkok, Thailand. Adults (> 18 years) with primary CRS, diagnosed using EPOS2020 criteria, were recruited alongside non‐CRS controls. Discriminant validity was assessed by comparing scores between CRS patients and non‐CRS controls. Concurrent validity was evaluated by correlating CRS‐PRO with the Thai version of the Sinonasal Outcome Test‐22 (SNOT‐22). Reliability was assessed using internal consistency (Cronbach's alpha) and test–retest reliability using intraclass correlation coefficient (ICC). Results: A total of 85 CRS patients and 40 non‐CRS controls were enrolled. The Thai CRS‐PRO was completed in (101.80 ± 26.36) seconds. CRS patients had significantly higher scores than controls (16 [10–24] vs. 2 [0–5], p < 0.001) (median [IQR]). CRS‐PRO demonstrated strong concurrent validity with SNOT‐22 ( ρ = 0.82, p < 0.001), high internal consistency (Cronbach's alpha = 0.89), and high test–retest reliability (ICC = 0.81, 95% confidence interval 0.72–0.88). Conclusions: The Thai‐translated CRS‐PRO has been developed and validated. It demonstrated significant discriminant validity between patients and non‐patients, a very strong correlation with the Thai version of SNOT‐22, and good reliability. Its brevity and time efficiency support its applicability in both clinical practice and research, enhancing its potential for widespread adoption.Keywords
This publication has 24 references indexed in Scilit:
- Evaluating health utility score through direct and indirect methods in patients with chronic rhinosinusitisInternational Forum of Allergy & Rhinology, 2024
- Chinese adaptation and validation of the chronic rhinosinusitis‐patient‐reported outcome: Assessment of health‐related quality‐of‐lifeInternational Forum of Allergy & Rhinology, 2023
- Health Utility Score in Thai Patients with Chronic Rhinosinusitis: Pre‐ and Postoperative AnalysesThe Laryngoscope, 2023
- Sensibility, specificity, and accuracy of the Sinonasal Outcome Test 8 (SNOT-8) in patients with chronic rhinosinusitis (CRS): a cross-sectional cohort studyEuropean Archives of Oto-Rhino-Laryngology, 2023
- Translation and Validation of the Thai Version of the Nasal Obstruction Symptom Evaluation (NOSE) ScaleOTO Open, 2023
- CRS‐PRO and SNOT‐22 correlations with type 2 inflammatory mediators in chronic rhinosinusitisInternational Forum of Allergy & Rhinology, 2022
- Responsiveness and convergent validity of the chronic rhinosinusitis patient‐reported outcome (CRS‐PRO) measure in CRS patients undergoing endoscopic sinus surgeryInternational Forum of Allergy & Rhinology, 2021
- Responsiveness and Convergent Validity of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO)The Journal of Allergy and Clinical Immunology: In Practice, 2020
- The validity and reliability of Thai Sinonasal Outcome Test-22European Archives of Oto-Rhino-Laryngology, 2016
- Making Sense of Methods and Measurement: Spearman-Rho Ranked-Order Correlation CoefficientClinical Simulation in Nursing, 2014